Twelve children (7 females, 5 males), of whom 7 were affected by JIA, 3 by idiopathic uveitis, 1 by early-onset sarcoidosis, and 1 by Behçet’s disease, were enrolled in Group 2, who received Adalimumab as second anti-TNF-α drug. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.